TGFBR2 and neoplasm: Additional genetic edits to enhance functionality, shield from immunosuppressive pressures and augment anti-tumor potency included CD52 KO to enable administration of anti-CD52 lymphodepleting antibodies, PD-1 KO to prevent premature CAR-T cell exhaustion, TGFBR2 KO to overcome TME-induced immunosuppression, Regnase-1 KO for enhanced functional persistence and CD74 KO to prevent formation of immunosuppressive Tregs.